Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.
Continue reading Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas
Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas originally appeared on DailyFinance on Fri, 28 Jan 2011 12:30:00.
Filed Under: Company News, Columns, Health Care, Genzyme Corporation , Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Novartis, Eli Lilly, Astrazeneca